Tirzepatide side effects: what the studies found
Real adverse event rates, clinical trial discontinuation numbers, and documented safety warnings from peer-reviewed literature.
This page has not yet been reviewed by a credentialed medical professional. It is educational and is not medical advice.
Safety summary: Tirzepatide
- Evidence level FDA-approved
- FDA approvedYes
- Trial discontinuation4.3% (5 mg), 7.1% (10 mg), and 6.2% (15 mg) in SURMOUNT-1 vs 2.6% on placebo.
- WADA sport statusNot prohibited
In short: Gastrointestinal events were most common and mostly mild to moderate, mainly during dose escalation. In SURMOUNT-1, treatment discontinuation due to adverse events ranged from 4.3% to 7.1% across tirzepatide arms vs 2.6% on placebo.
Risk of thyroid C-cell tumors: Tirzepatide causes thyroid C-cell adenomas and carcinomas in rodents. Contraindicated in individuals with personal/family history of MTC or MEN 2.
Most common side effects
Reported symptoms in clinical trials and published pharmacology literature:
| Symptom | Reported rate | Clinical context & notes |
|---|---|---|
| Nausea | 24% to 33% vs 9% placebo | Dose-dependent; highest at 15 mg and during dose escalations. |
| Diarrhea | 18% to 23% vs 7% placebo | Predominantly mild to moderate and transient. |
| Vomiting | 8% to 12% vs 2% placebo | More common during rapid eating or overeating. |
| Constipation | 11% to 17% vs 6% placebo | Associated with slowed gastrointestinal transit. |
| Dyspepsia & reflux | 8% to 10% | Often exacerbated by lying down soon after meals. |
| Injection site reactions | 3% to 4% | Localized erythema or pruritus, usually resolving in days. |
Serious risks and warnings
Potential adverse reactions and biological risks identified in research:
- Acute pancreatitis: Rare in trials, but drug must be stopped if persistent severe upper abdominal pain radiates to the back.
- Gallbladder disease: Cholelithiasis and acute cholecystitis associated with rapid adipose mass loss.
- Acute kidney injury: Secondary to dehydration from severe nausea or diarrhea.
- Severe gastrointestinal disease: Not recommended in patients with severe gastroparesis.
Contraindications
This compound should not be used in individuals with:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia type 2 (MEN 2)
- History of serious hypersensitivity
- Pregnancy
Common questions about Tirzepatide safety
Are tirzepatide side effects worse than semaglutide?
In the SURMOUNT-5 direct head-to-head obesity trial, overall gastrointestinal tolerability was comparable between tirzepatide and semaglutide, with similar rates of nausea and diarrhea occurring during dose escalation.
Can tirzepatide affect oral birth control pills?
Yes. Because tirzepatide delays gastric emptying, it can reduce peak absorption of oral contraceptive pills. The FDA prescribing label advises females using oral contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after initiation and after each dose escalation.
What happens if you miss a dose of tirzepatide?
If a dose is missed, it should be administered as soon as possible within 4 days (96 hours). If more than 4 days have passed, skip the missed dose and resume on the regularly scheduled day.